{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-007529","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.212356+00:00","generated_at":"2026-06-17T21:15:31.972367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa Therapeutics reports FY2022 net loss of $26.96M; provides clinical updates on (Z)-endoxifen trials","bullets":["Net loss of $26.96M ($0.21 diluted EPS) vs $20.6M loss in FY2021; operating expenses up 35% to $27.7M.","R&D expenses rose 64% to $15.1M, driven by clinical trials for (Z)-endoxifen and AT-H201 programs.","Cash, cash equivalents and restricted cash totaled $111M as of Dec 31, 2022, down from $136.5M a year earlier.","Initiated Phase 2 EVANGELINE study for (Z)-endoxifen in ER+/HER2- breast cancer; first patient dosed.","Invested $4.7M in Dynamic Cell Therapies, acquiring ~19% stake; new patent granted for enteric capsule formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-007529","json":"https://secwatch.observer/filing/0001437749-23-007529.json","markdown":"https://secwatch.observer/filing/0001437749-23-007529.md","text":"https://secwatch.observer/filing/0001437749-23-007529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/0001437749-23-007529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/atos20230315_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:15:31.972367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b565a0657020af83bb1a94fdbfbd82b5e589dde","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"On March 22, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2022 financial results and a Company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/0001437749-23-007529-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}